Antibody (Immunoglobulin)

Overview

Antibodies (immunoglobulins, Ig) are glycoproteins secreted at high rate by plasma cells — terminally differentiated B lymphocytes. Each molecule is built from two identical heavy chains and two identical light chains joined by disulfide bonds into the characteristic Y shape. The two "arms" of the Y each carry an antigen-binding site (Fab region); the "stem" is the Fc region that interacts with complement and Fc receptors on effector cells.

The human immune system can generate an estimated 10¹² or more distinct antibody specificities through V(D)J recombination and somatic hypermutation. Once a B cell encounters its cognate antigen and receives T helper cell (Tfh) signals in the germinal center, it undergoes class-switch recombination and affinity maturation, exiting as a long-lived plasma cell that secretes high-affinity, class-switched antibody for years to decades.

Antibodies mediate protection through four principal mechanisms: neutralization (Fab arms physically block pathogen surface proteins), opsonization (Fc tail recruits FcγR-bearing phagocytes), complement activation (classical pathway via C1q binding to Fc), and ADCC (FcγRIII on NK cells triggers cytotoxic killing of antibody-coated target cells). Together these mechanisms make antibodies the effector molecules underlying both natural infection immunity and vaccine-elicited protection.

Structure

Overall architecture

The canonical antibody monomer (exemplified by IgG) consists of four polypeptide chains: two identical heavy chains (~50 kDa each) and two identical light chains (~25 kDa each), linked by interchain disulfide bonds. The molecule is a symmetric homodimer at the heavy-chain level and is divided functionally into two Fab arms and one Fc region by the flexible hinge region.

        Fab arm                          Fab arm
   (antigen binding)               (antigen binding)
   ┌──────────┐                     ┌──────────┐
   │  VH + VL  │                    │  VH + VL  │
   │ CDR1,2,3  │◄─── Paratope ─────►│ CDR1,2,3  │
   │  (6 CDRs  │                    │  6 CDRs)  │
   │ CH1 + CL  │                    │ CH1 + CL  │
   └────┬──────┘                    └──────┬────┘
        └──────────────┬────────────────────┘
                  Hinge region
                (flexible Pro/Cys-rich; ~15 aa in IgG1)
                inter-heavy-chain disulfide bonds
                       │
                  ┌────┴─────┐
                  │ Fc region │
                  │  CH2+CH2  │ ← Asn297 glycan (N-linked)
                  │           │ ← C1q binding (complement)
                  │           │ ← FcγR binding (macrophage/NK)
                  │  CH3+CH3  │ ← FcRn binding (IgG half-life)
                  └───────────┘

Fab region (Fragment antigen-binding)

Each Fab arm is formed by the VH + CH1 domains of a heavy chain paired with the VL + CL domains of a light chain. The antigen-binding site (the paratope) is formed by six complementarity-determining region (CDR) loops — CDR1, CDR2, and CDR3 from VH, plus CDR1, CDR2, and CDR3 from VL. These six loops come together at the tip of each Fab arm to create a surface that is precisely complementary to the epitope on the antigen. CDR3 is the most variable loop because it spans the VH–D–JH junction, where V(D)J recombination introduces the greatest junctional diversity via random nucleotide addition/deletion by TdT.

Fc region (Fragment crystallizable)

The Fc region consists of the paired CH2 and CH3 domains of both heavy chains. It has a constant sequence (within each isotype subclass) and does not contact antigen. Instead, Fc serves as the interface for effector cells and serum proteins:

• C1q (complement): binds the CH2 domain of IgG1/IgG3 or the pentameric Fc of IgM → classical pathway activation
• FcγR (Fc gamma receptors, I/IIa/IIb/IIIa/IIIb): on macrophages, neutrophils, NK cells, monocytes → opsonophagocytosis, ADCC, ADCP, immune complex clearance
• FcRn (neonatal Fc receptor): on vascular endothelial cells → pH-dependent rescue of IgG from lysosomal degradation, extending half-life to ~21 days; also mediates placental IgG transfer

Hinge region

The hinge is a short, flexible, proline-rich segment between CH1 and CH2 that connects the two Fab arms to the Fc. Its flexibility allows the two Fab arms to swing independently and adopt variable angles, enabling bivalent binding to antigens on irregular surfaces. The hinge also harbours the interchain disulfide bonds between heavy chains. Hinge length and flexibility vary across isotypes: IgG3 has the longest hinge (~62 aa), IgA and IgD have intermediate hinges, while IgG1/2/4 have shorter hinges. The hinge is the protease-cleavage site exploited experimentally: papain cleaves above the disulfides → two separate Fab fragments + one Fc; pepsin cleaves below the disulfides → one bivalent F(ab′)₂ fragment + Fc fragments.

Light chains (κ and λ)

Each antibody bears either two κ or two λ light chains (never a mixture). Both types consist of one variable domain (VL) and one constant domain (CL). The κ:λ ratio in healthy human serum is approximately 2:1. While light chains contribute significantly to antigen binding via their CDRs, they have no direct effector function through the Fc path. However, light chains are shed into serum and urine ("free light chains", FLCs) and their measurement is diagnostically important in multiple myeloma and AL amyloidosis.

Glycosylation

IgG carries a single N-linked oligosaccharide at Asn297 of each CH2 domain (one per heavy chain, two per IgG molecule). This glycan is buried between the two CH2 domains and is essential for proper Fc conformation and effector function: removal of the glycan abolishes C1q binding and severely reduces FcγR affinity. The glycan composition modulates function — afucosylation increases FcγRIII affinity ~50-fold (enhanced ADCC); hypersialylation confers anti-inflammatory activity; hypogalactosylation is seen in RA and associated with increased complement activation. Therapeutic antibody engineers tune the glycan profile to optimise the desired effector balance.

Isotypes: The Five Immunoglobulin Classes

Class-switch recombination (CSR) allows a single B cell clone to change the constant region of its heavy chain — and thus the isotype — while keeping the same antigen-binding V region. The isotype determines the antibody’s physical form, half-life, tissue distribution, and effector capabilities.

Antigen Binding: CDRs, Affinity, and Avidity

Complementarity-determining regions (CDRs)

Six CDR loops form the paratope of each Fab arm: CDR-H1, CDR-H2, CDR-H3 from the heavy chain variable domain, and CDR-L1, CDR-L2, CDR-L3 from the light chain variable domain. The framework regions (FRs) between CDRs maintain the immunoglobulin fold scaffold but do not contact antigen. CDR lengths and sequences are the primary determinants of antibody specificity and affinity.

CDR3 (both heavy and light) is the most diverse CDR because it spans the recombination junction. In the heavy chain, CDR3 is formed at the VH–D–JH junctions, where TdT adds random N-nucleotides. CDR3 lengths and sequences vary enormously across the B cell repertoire, creating the dominant contribution to antigen-contact diversity.

Molecular interactions at the antibody–antigen interface

Antigen–antibody binding is non-covalent and reversible. It relies on a complementary fit between epitope and paratope through:

• Hydrogen bonds: between polar/charged groups (backbone NH/C=O, Asn, Gln, Tyr, Ser, etc.)
• Electrostatic interactions: salt bridges between oppositely charged residues (Arg, Lys vs. Asp, Glu)
• Van der Waals forces: short-range London dispersion forces from closely packed surfaces
• Hydrophobic interactions: burial of apolar residues away from solvent; often a major driving force at protein–protein interfaces

Binding affinity is quantified as the equilibrium dissociation constant K_d. Naïve IgM BCRs have K_d ~10⁻⁶ M (μM); after affinity maturation in germinal centers, mature IgG antibodies typically reach K_d ~10⁻⁹–10⁻¹² M (nM to pM). Therapeutic monoclonal antibodies are frequently engineered or selected at pM affinity.

Affinity vs. avidity

Effector Mechanisms

1. Neutralization

Antibody Fab arms physically block biologically active sites on pathogens or toxins, preventing host cell receptor engagement. Neutralization is purely a Fab-mediated function — no Fc effectors are required. Examples: anti-spike RBD antibodies blocking SARS-CoV-2 ACE2 binding; anti-hemagglutinin antibodies blocking influenza HA binding to sialic acid; anti-diphtheria toxin antibodies blocking receptor binding. Neutralization is the dominant protective mechanism measured by plaque-reduction neutralization tests (PRNT) and virus neutralization titers (VNT) as vaccine correlates of protection.

2. Opsonization

IgG coating pathogen surfaces (opsonization) dramatically enhances phagocytosis. FcγR-bearing professional phagocytes (macrophages, neutrophils, monocytes) bind the IgG Fc tail via activating FcγRI (CD64), FcγRIIa (CD32a), and FcγRIIIa (CD16a), triggering internalization of the antibody–pathogen complex and intracellular killing (oxidative burst + lysosomal enzymes). This is termed antibody-dependent cellular phagocytosis (ADCP).

3. Complement activation (classical pathway)

  IgG array on pathogen surface (or pentameric IgM)
               │
               ▼
        C1q recognises Fc (CH2 domain)
        C1q → C1r → C1s activation (C1 complex)
               │
               ▼
        C1s cleaves C4 → C4b (covalent attachment to surface) + C4a
        C4b + C2 → C4b2a (classical pathway C3 convertase)
               │
               ▼
        C3 → C3b (opsonin) + C3a (anaphylatoxin)
               │
               ├─ C3b on surface → CR1 on phagocytes → phagocytosis
               │
               ├─ C4b2a + C3b → C5 convertase → C5a + C5b
               │
               └─ C5b + C6-C9 → MAC (membrane attack complex)
                              → lysis of Gram-negative bacteria

IgM is the most potent activator because its pentameric Fc arrangement presents multiple C1q-binding sites simultaneously. Among IgG subclasses, IgG3 > IgG1 >> IgG2 >> IgG4 for classical pathway activation. At least 2–3 IgG Fc domains in proximity are required to activate C1q, hence antibody clustering on the antigen surface is required.

4. ADCC (Antibody-Dependent Cellular Cytotoxicity)

IgG bound to target cell surface antigens (e.g., viral proteins on infected cells, tumour antigens) presents Fc tails to FcγRIII (CD16) on NK cells. Engagement crosslinks CD16, triggering NK cell activation and release of perforin and granzymes → target cell apoptosis. ADCC is Fab-guided but Fc-executed. It requires no MHC class I recognition, making it effective against MHC-downregulating viruses and tumours. ADCC is a major mechanism of action for therapeutic antibodies such as trastuzumab (HER2), rituximab (CD20), and cetuximab (EGFR).

Somatic Hypermutation and Affinity Maturation

After antigen-activated B cells seed germinal centers (GCs) in secondary lymphoid organs, they enter a Darwinian selection cycle that dramatically improves antibody affinity:

1. Dark zone proliferation: GC B cells (centroblasts) proliferate rapidly. Activation-induced cytidine deaminase (AID, encoded by AICDA) deaminates cytosines to uracils in variable-region (V-region) DNA at a rate ~10⁻³ mutations/base/division — one million times the background rate. This introduces point mutations throughout V_H and V_L, predominantly targeting CDRs.
2. Light zone selection: Mutant B cells (centrocytes) move to the light zone and compete for limiting native antigen displayed on follicular dendritic cells (FDCs). B cells with BCRs carrying affinity-enhancing mutations capture more antigen, process it, and present more pMHC-II to Tfh cells. This results in more CD40L:CD40 signaling and more IL-21, giving high-affinity clones a survival and proliferative advantage.
3. Iterative cycles: B cells cycle between dark zone (mutate) and light zone (select) multiple times over 1–3 weeks. Each cycle preferentially enriches higher-affinity clones and eliminates lower-affinity or autoreactive ones (negative selection via Fas/FasL).
4. Exit: Affinity-matured B cells exit the GC as long-lived plasma cells (LLPCs) migrating to bone marrow niches where they continuously secrete high-affinity IgG for decades, or as memory B cells ready for rapid recall on antigen re-exposure.

Clinical Applications

Pathology

Cross-Atlas Connections

• Produced by B cell — antigen recognition via BCR (surface-bound antibody); germinal center reaction generates affinity-matured class-switched B cells
• Secreted by Plasma cell — terminally differentiated B cell; long-lived plasma cells in bone marrow secrete up to 2,000 antibody molecules per second continuously for decades
• Activates Complement C3 — IgG/IgM Fc binding to C1q initiates classical pathway → C3 convertase → C3b opsonization, C3a anaphylatoxin, and MAC
• Matured by T helper cell (Tfh) — follicular T helper cells provide CD40L, IL-21, and ICOS signals essential for germinal center reaction, class switching, and affinity maturation
• Recruits Macrophage — IgG Fc binds FcγR on macrophages → opsonophagocytosis (ADCP) and respiratory burst killing of opsonized pathogens
• Recruits Natural killer cell — IgG Fc binds FcγRIII (CD16) on NK cells → ADCC; NK cell releases perforin/granzymes → apoptosis of antibody-coated target cells